• Corporate policies

in page functions
  • Gavi's corporate policy frameworks seek to ensure efficiency, transparency and accountability.

  • 24 September 2012

    Access to information policy

    The Access to information policy sets out the categories of documents that shall be made publicly available to external audiences through the Gavi website and other appropriate means of communication, to operate in a transparent and accountable manner.

    11 March 2011

    Conflict of interest and ethics policies

    Gavi's conflict of interest policy protects the integrity of Gavi's decision-making processes, particularly in regard to the allocation and disbursement of resources. The ethics policy establishes standards of ethical conduct for activities of any member of the Secretariat, Board and Advisory Bodies.

    24 September 2012

    Document retention policy

    This policy governs the preservation and, where applicable, permissible destruction of certain Gavi documents. It is intended to meet recognised practices and accounting standards for retention periods and to provide guidance on the circumstances which could require longer or indefinite periods of document preservation.

    01 April 2011

    Evaluation policy

    For an alliance whose innovative methods are often held up as models for others to imitate, it is essential that Gavi evaluates "lessons learned". It does this through commissioned studies that are guided by its evaluation policy.

    11 March 2011

    Procurement policy

    Gavi’s procurement policy aims to ensure greater transparency and optimisation of services resulting in lower costs, improved quality of services and longer term partnerships.

    28 November 2013

    Value statements

    The Vaccine Alliance is committed to fulfilling its social and ethical responsibilities to the global community. These statements outline the values along which it operates.

  • US$ 80-100 billion

    Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

    Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

    More facts...

close icon

modal window here